Physician profile
Clare E Skora
NPI 1902223373
$3,183.47
in general payments reported to CMS, 2019-2025
10 companies · $660 in 2025
The $660 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $33.76 · 2021: $231 · 2022: $447 · 2023: $769 · 2024: $1,042 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,236 · Travel and Lodging: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,235.92 |
| Travel and Lodging | $235.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $881.06 | 2024-2025 | Fintepla, Briviact, Nayzilam |
| Neurelis, INC. | $730.63 | 2020-2025 | Valtoco |
| Livanova USA, INC. | $520.33 | 2022-2023 | Vns Therapy |
| Sk Life Science, INC. | $272.43 | 2021-2024 | |
| Neuropace, INC. | $195.05 | 2020-2024 | |
| Cadwell Industries, INC | $156.00 | 2023 | |
| Jazz Pharmaceuticals INC. | $155.37 | 2022-2024 | |
| Aquestive Therapeutics, INC. | $143.81 | 2021 | |
| Azurity Pharmaceuticals, INC. | $64.54 | 2025 | Zonisade |
| Monteris Medical Corporation | $64.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clare Skora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.